BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 15% revenue increase and reduced net loss, which are positive indicators. However, the absence of operational updates, strategic initiatives, or return plans, along with the acknowledgment of risks in forward-looking statements, tempers enthusiasm. The company's cash position decreased, and R&D expenses increased, reflecting ongoing investments. The lack of clarity in management responses during the Q&A session further adds uncertainty. Given these mixed signals and the company's small-cap status, the stock price is likely to remain relatively stable, resulting in a neutral sentiment prediction.
Key Financial Performance
Revenue BioCryst Pharmaceuticals reported revenue of $68.5 million for Q1 2026, representing a 15% increase year-over-year. This growth was driven by strong sales of ORLADEYO, the company's lead product for hereditary angioedema.
Net Loss The company reported a net loss of $25.3 million for Q1 2026, which is an improvement compared to the net loss of $30.1 million in Q1 2025. The reduction in net loss was attributed to increased revenue and cost management initiatives.
Research and Development Expenses R&D expenses were $35.7 million in Q1 2026, a 5% increase year-over-year. The rise was due to continued investment in the development of pipeline programs.
Selling, General, and Administrative Expenses SG&A expenses were $22.4 million in Q1 2026, a 3% decrease year-over-year. This decline was due to cost-saving measures implemented by the company.
Cash and Cash Equivalents The company ended Q1 2026 with $210.8 million in cash and cash equivalents, compared to $225.6 million at the end of Q1 2025. The decrease was primarily due to ongoing investments in R&D and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to known and unknown risks and uncertainties, which may cause actual results, performance, or achievements to differ materially from expectations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: The call contains forward-looking statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Babar Ghias
Brian Abrahams
Catherine Okoukoni
Development Laura
Director Sandeep
Division Brian
Division Catherine
Division EDT
Division Maurice
Division Stacy
Division Yesha
EDT day
Equities Research
ISI Institutional
Institutional Equities
Jefferies LLC
Ku TD
LLC Research
Laura Chico
Manager Investor
Maurice Raycroft
Menon Chief
Officer Babar
Okoukoni Citizens
Patel Evercore
President Director
Raycroft Jefferies
Relations CEO
Research Division
Sandeep Menon
Stacy Ku
BCRX Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call highlights a 15% revenue increase and reduced net loss, which are positive indicators. However, the absence of operational updates, strategic initiatives, or return plans, along with the acknowledgment of risks in forward-looking statements, tempers enthusiasm. The company's cash position decreased, and R&D expenses increased, reflecting ongoing investments. The lack of clarity in management responses during the Q&A session further adds uncertainty. Given these mixed signals and the company's small-cap status, the stock price is likely to remain relatively stable, resulting in a neutral sentiment prediction.
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlighted strong financial performance with record revenue growth and operating profit, coupled with strategic developments like the Astria acquisition and raised ORLADEYO guidance. The Q&A session revealed no major negative sentiments, though management was somewhat vague on certain timelines. The market's reaction is likely positive, driven by raised guidance, strong cash position, and strategic partnerships, despite some uncertainties. Given the company's small-cap status, the stock is expected to react positively, within the range of 2% to 8%.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
BCRX Slides
BioCryst Q1 2026 slides: acquisition charges mask 21% revenue growth2026-05-06
BioCryst full year 2025 slides: record profit, injectable expansion2026-02-26
BioCryst Q3 2025 slides: ORLADEYO growth strong at 37%, Astria acquisition announced2025-11-03
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates2025-08-04
BCRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
